Differential Expression of IL-17, 22 and 23 in the Progression of Colorectal Cancer in Patients with K-ras Mutation: Ras Signal Inhibition and Crosstalk with GM-CSF and IFN-γ

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Petanidis, Savvas ^a   Anestakis, Doxakis ^a   Argyraki, Maria ^a   Hadzopoulou Cladaras, Margarita ^b   Salifoglou, Athanasios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; K RAS PROTEIN; MANUMYCIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL GROWTH; CELL VIABILITY; CODON; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; K RAS GENE; MAJOR CLINICAL STUDY; PROMOTER REGION; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CACO-2 CELLS; CELL SURVIVAL; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION PROFILING; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKINS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYENES; POLYUNSATURATED ALKAMIDES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84883615553     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073616     Document Type: Article

References (53)

1. Tenesa A, Dunlop MG, (2009) New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 10: 353-358.
2. Grady WM, (2004) Genomic instability and colon cancer. Cancer Metastasis Rev 23: 11-27.
3. Shih IM, Zhou W, Goodman SN, Lengauer C, Kinzler KW, et al. (2001) Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res 61: 818-822.
4. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, et al. (2009) PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20: 84-90.
5. Yamagata S, Muto T, Uchida Y, Masaki T, Higuchi Y, et al. (1995) Polypoid growth and K-ras codon 12 mutation in colorectal cancer. Cancer 75: 953-957.
6. Schubbert S, Shannon K, Bollag G, (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7: 295-308.
7. Vendramini-Costa DB, Carvalho JE, (2012) Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 18: 3831-3852.
8. Rizzo A, Pallone F, Monteleone G, Fantini MC, (2011) Intestinal inflammation and colorectal cancer: a double-edged sword. World J Gastroenterol 17: 3092-3100.
9. Kolls JK, Lindén A, (2004) Interleukin-17 family members and inflammation. Immunity 21: 467-476.
10. Martin-Orozco N, Dong C, (2009) The IL-17/IL-23 axis of inflammation in cancer: friend or foe? Curr Opin Investig Drugs 10: 543-549.
11. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, et al. (2009) STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 206: 1465-1472.
12. Zhang W, Chen Y, Wei HR, Zheng C, Sun R, et al. (2008) Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 14: 6432-6439.
13. Ahern PP, Izcue A, Maloy KJ, Powrie F, (2008) The interleukin-23 axis in intestinal inflammation. Immunol Rev 226: 147-159.
14. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, et al. (2006) IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116: 1310-1316.
15. Zelante T, De Luca A, Bonifazi P, Montagnoli C, Bozza S, et al. (2007) IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 37: 2695-2706.
16. Ward AF, Braun BS, Shannon KM, (2012) Targeting oncogenic Ras signaling in hematologic malignancies. Blood 120: 3397-3406.
17. Gremer L, Merbitz-Zahradnik T, Dvorsky R, Cirstea IC, Kratz CP, et al. (2011) Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Hum Mutat 32: 33-43.
18. Ling J, Kang Y, Zhao R, Xia Q, Lee DF, et al. (2012) KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feed forward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 21: 105-120.
19. Rowley M, Van Ness B, (2002) Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response. Oncogene 2: 8769-8775.
20. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, et al. (2011) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2: 135-164.
21. Sunaga N, Imai H, Shimizu K, Shames DS, Kakegawa S, et al. (2012) Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. Int J Cancer 130: 1733-1744.
22. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, et al. (2012) Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491: 254-258.
23. Beaupre D, Talpaz M, Frank C, Cristian RJ, Roth JA, et al. (1999) Autocrine Interleukin-1β Production in Leukemia. Evidence for the Involvement of Mutated RAS6. Cancer Res 59: 2971-2980.
24. Tsimberidou AM, Chandhasin C, Kurzrock R, (2010) Farnesyltransferase inhibitors: where are we now? Expert Opin Investig Drugs 19: 1569-1580.
25. Braun T, Fenaux P, (2008) Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 141: 576-586.
26. Broughton SE, Dhagat U, Hercus TR, Nero TL, Grimbaldeston MA, et al. (2012) The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol Rev 250: 277-302.
27. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, et al. (2003) Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17: 1263-1293.
28. Lee MS, Kim HS, Yeon JT, Choi SW, Chun CH, et al. (2009) GM-CSF regulates fusion of mononuclear osteoclasts into bone-resorbing osteoclasts by activating the Ras/ERK pathway. J Immunol 183: 3390-3399.
29. Choi JK, Kim KH, Park H, Park SR, Choi BH, (2011) Granulocyte macrophage-colony stimulating factor shows anti-apoptotic activity in neural progenitor cells via JAK/STAT5-Bcl-2 pathway. Apoptosis 16: 127-134.
30. Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D, (2012) Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21: 836-847.
31. Wang J, Liu Y, Li Z, Du J, Ryu MJ, et al. (2010) Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood 116: 5991-6002.
32. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, et al. (2001) Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92: 441-450.
33. Hu X, Ivashkiv LB, (2009) Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 31: 539-550.
34. Weyand CM, Younge BR, Goronzy JJ, (2011) IFN-γ and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol 23: 43-49.
35. Nelson N, Kanno Y, Hong C, Contursi C, Fujita T, et al. (1996) Expression of IFN regulatory factor family proteins in lymphocytes. Induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation. J Immunol 156: 3711-3720.
36. Riemensberger J, Böhle A, Brandau S, (2002) IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 127: 20-26.
37. Traversari C, Meazza R, Coppolecchia M, Basso S, Verrecchia A, et al. (1997) IFN-gamma gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer. Gene Ther 4: 1029-1035.
38. Shankaran V, Ikeda HR, Bruce AT, White JM, Swanson PE, et al. (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1011.
39. Huang Y, Horvath CM, Waxman S, (2000) Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin, and phenylbutyrate. Cancer Res 60: 3200-3206.
40. Hira SK, Manna PP, (2012) Down regulation of CD24 and HER-2/neu in breast carcinoma cells by activated human dendritic cell. Role of STAT3. Cell Immunol 275: 69-79.
41. Fulda S, Debatin KM, (2002) IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21: 2295-2308.
42. Windbichler GH, Hausmaninger HR, Stummvoll W, Graf AH, Kainz C, et al. (2000) Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 82: 1138-1144.
43. Krown SE, (1991) Interferon and other biologic agents for the treatment of Kaposi's sarcoma. Hematol Oncol Clin North Am 5: 311-322.
44. Hatanaka K, Suzuki K, Miura Y, Yoshida K, Ohnami S, et al. (2004) Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer. J Gene Med 6: 1139-1148.
45. Guthrie GJ, Roxburgh CS, Horgan PG, McMillan DC, (2013) Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev 39: 89-96.
46. Clevers HR, (2004) At the crossroads of inflammation and cancer Cell. 118: 671-674.
47. Schneikert J, Behrens J, (2007) The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut 56: 417-425.
48. Rustgi AK, (2007) The genetics of hereditary colon cancer. Genes Dev 21: 2525-2538.
49. Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, et al. (2012) Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 72: 779-789.
50. Yap TA, Sandhu SK, Carden CP, de Bono JS, (2011) Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 61: 31-49.
51. Koehne CH, Dubois RN, (2004) COX-2 inhibition and colorectal cancer. Semin Oncol 2: 12-21.
52. Nakada Y, Saito S, Ohzawa K, Morioka CY, Kita K, et al. (2001) Antisense oligonucleotides specific to mutated K-ras genes inhibit invasiveness of human pancreatic cancer cell lines. Pancreatology 1: 314-319.
53. Cunningham CC, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, et al. (2001) A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 5: 1265-1271.